Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 5, 2022

Acadia Pharmaceuticals receives CRL for sNDA for NUPLAZID to treat ADP

Acadia Pharmaceuticals has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) on its supplemental New Drug Application (sNDA) for NUPLAZID (pimavanserin).

Image: Around 30% of patients with AD experience psychosis, commonly consisting of hallucinations and delusions. Credit: Gerd Altmann from Pixabay.